Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

NCT00154102 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1221

Enrollment

INDUSTRY

Sponsor class

Conditions

Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Interventions

DRUG: Cetuximab
DRUG: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

Sponsor

Merck KGaA, Darmstadt, Germany